Skin Disorder

Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of almost 164%. Dermata's pipeline includes DMT310, a once-weekly topical product for acne, psoriasis & rosacea, and...

The FDA has issued a Complete Response Letter (CRL) regarding Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) marketing application seeking approval for VP-102 for molluscum contagiosum, a highly contagious viral skin disease. The FDA had previously extended the Prescription...

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease. The 138-...

The FDA has approved AbbVie Inc's (NYSE: ABBV) Dalvance (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth.  Dalvance is the first single-dose option administered as a 30-minute intravenous...

Ahead of Phase 3 data readout in the second half of next year, Castle Creek Biosciences Inc (NASDAQ: CCBS) seeks to make NASDAQ debut under the symbol CCBS. The Company's advanced product candidate, dabocemagene autoficel or D-Fi, is under development for recessive dystrophic...

Celldex Therapeutics Inc (NASDAQ: CLDX) has priced an underwritten public offering of around 5.9 million shares at $42.00 per share, representing a discount of about 6% from the last close price of $44.6 on Tuesday. Gross proceeds are expected to approximately $250 million. The Company...

Krystal Biotech Inc (NASDAQ: KRYS) announced updated results from the Phase 1/2 trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis (ARCI) associated with mutations in the TGM1 gene.  Data showed that repeat doses of KB105...

Journey Medical Corporation, a partner company of Fortress Biotech Inc (NASDAQ: FBIO), has entered into a collaborative development and commercialization agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) for the DFD-29 (Minocycline Modified Release Capsules...

Novan Inc (NASDAQ: NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical antiviral gel, for the treatment of molluscum contagiosum. Molluscum is a common, contagious skin infection caused by the molluscipoxvirus...

The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a...

Amgen Inc (NASDAQ: AMGN) and Kyowa Kirin Co Ltd (OTC: KYKOF) have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases. In...

Timber Pharmaceuticals Inc (NYSE: TMBR) has completed enrollment in the Phase 2b CONTROL study evaluating TMB-001, a topical pharmaceutical composition of isotretinoin, for moderate to severe subtypes of congenital ichthyosis (CI). The company said that based on the positive safety and...

Alphabet Inc’s (NASDAQ: GOOG) latest foray into health care is a web tool that uses artificial intelligence to help people identify skin, hair, or nail conditions. A trial of the “dermatology assist tool” unveiled at the company’s annual developer conference, Google IO...

Cabaletta Bio Inc (NASDAQ: CABA) has announced acute safety data from the first dose cohort of the ongoing DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus Vulgaris (mPV). In the first cohort of three patients dosed with DSG3-CAART, there were no...

The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP). Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the...